|Bid||0.00 x 800|
|Ask||0.00 x 900|
|Day's Range||238.19 - 240.93|
|52 Week Range||226.15 - 267.37|
|Beta (5Y Monthly)||0.76|
|PE Ratio (TTM)||37.58|
|Earnings Date||Nov 04, 2021|
|Forward Dividend & Yield||3.32 (1.38%)|
|Ex-Dividend Date||Sep 08, 2021|
|1y Target Est||268.13|
Subscribe to Yahoo Finance Plus to view Fair Value for BDXLearn more
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a new strategy to advance environmental, social and governance (ESG) initiatives, as well as a suite of goals for 2030 and beyond that focus on enhancing stewardship of the company, the planet, community and human health.
BD's (BDX) latest manufacturing line is expected to not only boost supply capacity but also provide priority access to needles and syringes to the U.S. government.
BD's (BDX) Rotarex Atherectomy System receives expanded 510 (k) clearance from the FDA that can help in the treatment of in-stent restenosis in the United States.